Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK going nowhere while key vaccines struggle, says US bank
08:44am, Tuesday, 12'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) looks undervalued, but the problem is that there is nothing on the horizon to change that perception according to analysts at US bank Jefferies. Downgrading its investment
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
07:20am, Tuesday, 12'th Nov 2024
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position incre
GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays
02:33pm, Friday, 08'th Nov 2024
Barclays lowered the firm's price target on GSK to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.
Canada approves GSK's RSV vaccine for adults aged 50 to 59
09:51am, Tuesday, 05'th Nov 2024
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
03:06pm, Wednesday, 30'th Oct 2024
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
GSK plc (GSK) Q3 2024 Earnings Call Transcript
01:18pm, Wednesday, 30'th Oct 2024
GSK plc (NYSE:GSK ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcar
GSK (GSK) Q3 Earnings Surpass Estimates
10:05am, Wednesday, 30'th Oct 2024
GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago.
GSK: Earnings Confirm It's On Track To Meet Guidance
09:19am, Wednesday, 30'th Oct 2024
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS gr
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
09:02am, Wednesday, 30'th Oct 2024
GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy skidded.
GSK's Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024
08:58am, Wednesday, 30'th Oct 2024
Wednesday, GSK Plc GSK reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of $10.78 bi
GSK Stock Drops as UK Firm Posts Underwhelming Results
08:40am, Wednesday, 30'th Oct 2024
GSK's (GSK) shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated quarterly sales and lowered its projection for vaccine sales.
GSK cuts vaccine sales target on reduced demand
07:17am, Wednesday, 30'th Oct 2024
U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year after what it called lower-than-expected demand.
GSK falls 3% as vaccines disappoint (again)
04:17am, Wednesday, 30'th Oct 2024
Dedicated followers of GSK PLC (LSE:GSK, NYSE:GSK) will have been aware of analysts' growing unease around the performance of its vaccine franchise - backed up by prescription data. Third-quarter resu
GSK lowers 2024 vaccine sales forecast
03:06am, Wednesday, 30'th Oct 2024
GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
06:30pm, Monday, 28'th Oct 2024
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for
